Depression during pregnancy is frequently treated with the selective serotonin reuptake inhibitor, fluoxetine (FX). FX increases serotonergic neurotransmission and serotonin plays a role in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. We have therefore investigated the effect of chronic administration of FX to the pregnant ewe on the maternal and fetal HPA axes. Nineteen late-gestation sheep were surgically prepared for chronic study of the fetus. FX (n ϭ 7, 98.5 g/kg/d) or sterile water (control, n ϭ 8) was administered to the ewe for 8 d by constant rate i.v. infusion with an initial FX bolus dose of 70 mg. Maternal and fetal plasma ACTH and cortisol concentrations were determined at 0700 h each day. Maternal plasma ACTH concentrations fell on infusion d 2, but no changes were observed in maternal plasma cortisol concentrations. Fetal plasma ACTH concentrations increased on infusion d 7, and fetal plasma cortisol concentrations increased on infusion d 6, 7, and 8 in the FX group. In addition, the regression coefficient for the relationship between fetal ACTH and cortisol levels was significantly greater in the FX group compared with the control group. Thus, maternal FX treatment increased fetal plasma cortisol concentration. These results are of particular interest in the context that exposure of the fetus to excess glucocorticoids at critical windows during development has been shown to increase the risk of poor health outcomes in later life. Clinical depression occurs in 5-15% of pregnant women (1). Treatment of depression during pregnancy is important to fetal outcome by preventing poor maternal self-care and nutrition, disturbed sleep, lack of prenatal care, increased exposure to alcohol and drugs, and a higher risk of suicide by the mother (1). Depression at 28 wk gestation is related to an increase in negative pregnancy outcome, including an increased risk of low-birth-weight newborns, preterm delivery, and small-forgestational-age newborns (2). FX is a SSRI that increases serotonergic neurotransmission and is prescribed clinically for the treatment of depression, obsessive-compulsive disorder, and bulimia (3). It and other SSRIs have become increasingly used for the treatment of depression in pregnancy because of their effectiveness and lower incidence of maternal side effects and wider safety margin compared with tricyclic antidepressants and monoamine oxidase inhibitors (4, 5). However, there have been several reports that use of these drugs during pregnancy can increase the incidence of adverse pregnancy outcomes, including preterm delivery, fetal growth restriction, and poor neonatal adaptation (5-8). There is also evidence for postnatal consequences of prenatal SSRI exposure, including reduced weight gain, slight delays in psychomotor development and motor movement control, and our own findings of reduced facial and heart rate responses to painful stimuli (9 -11). 
Clinical depression occurs in 5-15% of pregnant women (1) . Treatment of depression during pregnancy is important to fetal outcome by preventing poor maternal self-care and nutrition, disturbed sleep, lack of prenatal care, increased exposure to alcohol and drugs, and a higher risk of suicide by the mother (1) . Depression at 28 wk gestation is related to an increase in negative pregnancy outcome, including an increased risk of low-birth-weight newborns, preterm delivery, and small-forgestational-age newborns (2) . FX is a SSRI that increases serotonergic neurotransmission and is prescribed clinically for the treatment of depression, obsessive-compulsive disorder, and bulimia (3) . It and other SSRIs have become increasingly used for the treatment of depression in pregnancy because of their effectiveness and lower incidence of maternal side effects and wider safety margin compared with tricyclic antidepressants and monoamine oxidase inhibitors (4, 5) . However, there have been several reports that use of these drugs during pregnancy can increase the incidence of adverse pregnancy outcomes, including preterm delivery, fetal growth restriction, and poor neonatal adaptation (5) (6) (7) (8) . There is also evidence for postnatal consequences of prenatal SSRI exposure, including reduced weight gain, slight delays in psychomotor development and motor movement control, and our own findings of reduced facial and heart rate responses to painful stimuli (9 -11).
FX and other SSRIs increase extracellular serotonin (5-HT) levels acutely and serotonergic neurotransmission chronically, and these actions could underlie the reported adverse effects of these agents on pregnancy outcome and postnatal development (7, 10, 12) . Serotonin plays a major role in the regulation of the HPA axis and adrenocortical secretion of cortisol (13) . The actions of serotonin, released by neurons originating in the midbrain raphe nucleus, are mediated by 5-HT 1A and 5-HT 2A/2C receptors in the paraventricular nucleus of the hypothalamus (14 -17) .
Basal ACTH and cortisol plasma concentrations did not change in humans receiving 20 mg FX for 20 d (18) . Most studies of chronic FX treatment, however, have focused on the neuroendocrine responses to a challenge of the serotonergic system with either 5-hydroxytryptophan (5-HTP), the precursor to 5-HT, or a 5-HT 1A agonist. Compared with controls, an attenuated ACTH and cortisol/corticosterone response to 5-HT 1A activation occurred after chronic FX treatment in humans (18, 19) and rats (20 -22) . Rats treated with 10 mg/kg FX for 21 d exhibited attenuated ACTH and cortisol responses to a 5-HT 1A agonist (8-OH-DPAT) (21) . The FX-elicited blunting of ACTH and cortisol responses to 5-HT 1A receptor stimulation appears to involve desensitization of postsynaptic 5-HT 1A receptors (19) , whereas the antidepressant actions of FX involve desensitization of presynaptic 5-HT 1A autoreceptors (3). Taken together, these studies illustrate that our current knowledge of the effects of FX on the endocrine system without serotoninergic challenge is incomplete. Furthermore, no studies have investigated the impact of maternal FX treatment on the fetal endocrine system.
Placental transfer of FX has been demonstrated in the rat (23), human (24) , and sheep (25) . In adults, FX is metabolized to norfluoxetine (NFX), which also has antidepressant activity; however, in pregnant sheep, NFX has not been detected in the fetus after fetal drug administration, suggesting that FX is not metabolized in the fetus (24, 26) . FX may, however, have similar effects in the fetus as in the adult on serotonin neurotransmission and HPA axis function. However, only one study has investigated the interaction between serotonin and the fetal HPA axis. Intravenous infusion of 5-HTP to the sheep fetus at 110 and 130 d gestation increased serotonin in hypothalamic tissue (27) . Thus, our hypothesis is that maternal FX treatment in sheep will increase fetal HPA axis function as measured by an increase in fetal plasma ACTH and cortisol concentration.
MATERIALS AND METHODS
Animals and surgical preparation. Nineteen time-bred Dorset/Suffolk cross, pregnant sheep were surgically prepared between 118 and 122 d gestation (term, 147 d). All experimental protocols and procedures performed on the sheep conformed to the guidelines of the Canadian Council on Animal Care and were approved by The University of British Columbia Animal Care Committee. Surgical procedures have been described in detail previously (28) . Briefly, anesthesia was induced with 1 g pentothal and maintained with 1.5% isoflurane after intubation. A midline incision in the maternal abdomen allowed access to the uterus to expose the fetus for implantation of polyvinyl catheters (Tygon, Akron, OH, U.S.A.) in the trachea, femoral arteries, lateral tarsal vein, and amniotic cavity. As previously reported (12, 29) , animals were instrumented for measurement of fetal behavioral state and uterine artery blood flow.
Experimental protocol. Ewes were housed in a 12:12 light/ dark cycle (lights on at 0600 h) with grain and hay once daily between 0830 and 0900 h and additional hay between 1530 and 1600 h. Ewes recovered for 3-4 d after surgery before experiments began. A preinfusion day preceded an 8-d infusion of either sterile water (n ϭ 8) or FX (n ϭ 7). The control group consisted of six female and two male fetuses, whereas the FX group consisted of three female and four male fetuses. There were one singleton, six twins, and one set of triplets in the control group and three singletons and four twins in the FX group. At 0700 h on infusion d 1, a 10-mL bolus injection of either 70 mg FX or sterile water was given over 2 min into the maternal femoral vein catheter followed by continuous infusion of 98.5 g/kg/d FX or an equivalent volume of sterile water for 8 d. The loading dose and infusion rate were calculated based on volume of distribution and systemic clearance data obtained from FX i.v. bolus pharmacokinetic studies in pregnant sheep previously performed in our laboratory (25) . At 0700 h each day, maternal and fetal blood samples were collected for analysis of blood gases (1 mL) and plasma concentration of FX, cortisol, and ACTH (1.5 mL) and stored at Ϫ20°C for 2 wk and then at Ϫ80°C. To limit total blood volume removed, not all hormones were measured in all animals at all time points. All fetuses delivered spontaneously (12) .
Blood gas analysis. Blood samples were analysed for pH, PCO 2 and PO 2 with an IL 1306 pH/blood gas analyser (Allied Instrumentation Laboratory, Milan, Italy) and temperature corrected to 39.5°C for fetal samples and 39°C for maternal samples. Hb and oxygen saturation were measured with an OSM-2 Hemoximeter (Radiometer, Copenhagen, Denmark).
Fluoxetine analysis. A rapid, sensitive, and selective chiral assay for FX and NFX enantiomers using gas chromatography mass spectrometry with selective ion monitoring developed in our laboratory was used for plasma FX analysis as previously described (25) . Samples were analyzed for plasma FX and NFX concentrations only if maternal and fetal blood samples were collected at all time points in the protocols from 0700 h on the preinfusion day to 72 h postinfusion (n ϭ 6).
ACTH hormone RIA. Plasma concentrations of immunoreactive ACTH were determined using an 125 I RIA kit (ICN Biomedicals, Seven Hills, NSW, Australia). The intra-assay coefficient of variation was Ͻ10% and the interassay coefficient of variation was 14.6%. The rabbit antihuman ACTH 1339 had a cross reactivity of Ͻ0.01% with ␣-melanocytestimulating hormone, ␤-endorphin, ␣-lipotropin, and ␤-lipotropin. The sensitivity of the assay was 7 pg/mL (30) .
Cortisol RIA. Total cortisol plasma concentration determination was performed using an 125 I RIA kit (Orion Diagnostica, Espo, Finland). The average efficiency of recovery of 125 I cortisol using dichloromethane extraction was 90% (31) . The sensitivity of the assay was 0.39 nmol/L. The rabbit anticortisol antibody cross-reacted Ͻ1% with cortisone and 17-hy-41 FETAL AND MATERNAL HPA RESPONSE TO FX droxyprogesterone and Ͻ0.01% with aldosterone, pregnenolone, estradiol, and progesterone. The inter-and intraassay coefficients of variation were Ͻ10%.
Statistical analysis. Results are presented as means Ϯ SEM. Blood gas, cardiovascular, and hormone data were analysed using repeated measures ANOVA followed by post hoc Fishers LSD test to determine the difference between the control and FX groups at each time point (p Ͻ 0.05) (denoted by a when p Ͻ 0.05) using NCSS Statistical Software (Kaysville, UT. U.S.A.). In addition, the effect of time on changes in measurements from preinfusion day (denoted by b in the control group and c in the FX group) was determined using repeated measures ANOVA followed by post hoc Fishers t tests (p Ͻ 0.05). Note that the preinfusion and infusion d 1 values are pre-FX exposure. Regression analysis of the relationship between fetal ACTH and cortisol concentrations was accomplished using the least squares method. Animals were excluded from analysis if the fetal cortisol plasma concentration was Ͼ15 nmol/L on the preinfusion day, as this was an indication that a premature prepartum increase in cortisol may have been present in these animals. One fetus in the FX-treated group died just before the onset of labor. Fetal blood gas and behavioral parameters were in the normal ranges until about 12 h before death. Accordingly, data from this animal were used only up to infusion d 5. Thus, cortisol and ACTH data were analyzed from eight control and seven FX-treated animals.
RESULTS

Fetal outcome.
On infusion d 8, mean gestational age was 135.4 Ϯ 0.6 d in the control group and 135.6 Ϯ 0.7 d in the FX group and the number of days before delivery occurred after the end of the infusion period was 7.1 Ϯ 1.6 in the control group and 6.3 Ϯ 1.3 in the FX group. Birth weight was 3072.8 Ϯ 299 g in the control group and 3645 Ϯ 252 in the FX group. There was no significant difference in gestational age, number of days before delivery, or birth weight between the two groups. In the control group, seven of the fetuses were born alive and there were one intrauterine and two intrapartum deaths. In the FX group, four of the fetuses were born alive, but there was one neonatal death. There were also two intrapartum deaths and one death just before the onset of labor.
Maternal and fetal plasma fluoxetine concentration. On infusion d 1, FX levels in both the ewe and fetus peaked 5 min Table 2 . Fetal oxygen saturation was also lower (p Ͻ 0.05) than the preinfusion day value (59.1 Ϯ 3.1%) on infusion d 2, 4, 5, 6, 7, and 8 in the FX group. A decrease in oxygen saturation (p Ͻ 0.05) was also observed in the control group on infusion d 4, 5, 6, 7, and 8 compared with the preinfusion day (55.7 Ϯ 4.1%), with the maximum drop of 9.8 Ϯ 2.6% on infusion d 8. Fetal pH was also lower (p Ͻ 0.05) on infusion d 4, 6, and 7 than on the preinfusion day in the FX group. There were no changes in PCO 2 in either the control or FX groups; however, Hb concentrations decreased significantly in the control group on infusion d 3, 4, 5, 6, 7, and 8. No changes in the daily average arterial pressure were observed in the ewes or fetuses within or between the control (n ϭ 5) and FX (n ϭ 6) groups throughout the experimental period (Table 3) .
Plasma ACTH and cortisol concentrations. There was no significant difference in maternal or fetal ACTH between the control and FX groups during the preinfusion period (Fig. 1, A  and B) . There was, however, a significant (p Ͻ 0.05) fall from the preinfusion day in maternal plasma ACTH concentrations in the FX group on infusion d 2 and 3 (Fig. 1A) , the maximum fall occurring on infusion d 2 (Ϫ38.0 Ϯ 11.9 pg/mL). In contrast, there were no significant changes in maternal ACTH throughout the period of the infusion in the control group. Maternal cortisol concentrations did not change throughout the infusion period in either the FX or control group (Fig. 2A) . When ACTH and cortisol concentrations early in the protocol (average concentration on the preinfusion day, infusion d 1 and 2) and late in the protocol (average concentration on infusion d 5-8) were pooled, there was a significant increase in maternal cortisol on infusion d 5-8 in the FX group (46.8 Ϯ 11.6 nmol/L) compared with preinfusion to infusion d 2 (24.7 Ϯ 3.4 nmol/L) in the absence of any change in maternal ACTH.
In the fetus, there was a significant (p Ͻ 0.05) increase in plasma ACTH concentrations from 37.0 Ϯ 7.9 pg/mL on preinfusion day to 75.7 Ϯ 20.1 on infusion d 7 in the FX group (Fig. 1B) . There was a significant increase in the fetal plasma cortisol concentrations on infusion d 6, 7, and 8 compared with the preinfusion day in both the control and FX groups (Fig.  2B) . The maximum change in fetal cortisol occurred on infu- There was a significant relationship between plasma cortisol (Y) and ACTH (X) concentrations in both the FX and control Data given as mean Ϯ SEM. No significant differences were observed between the control and FX group or across the experimental period in either group. Preinf, preinfusion day; Inf, infusion day; Con, control. 
DISCUSSION
Our results indicate that an 8-d maternal i.v. infusion of FX has little effect on the maternal pituitary-adrenal axis while increasing the magnitude of the normal prepartum rise in fetal plasma cortisol concentration. Although there was a small fall in maternal plasma ACTH on infusion d 2 and 3 in the FX, but not the control group, overall there was no significant effect of FX treatment on maternal plasma cortisol concentration. In contrast, there was a greater rise in fetal plasma ACTH and cortisol in the FX group when compared with the control fetuses.
It has been reported that fetal ACTH plasma levels increase progressively between 110 and 140 d gestation, whereas fetal cortisol levels remain low between 110 -120 d and increase between 125-140 d gestation (32) . McMillen et al. (33) also found that fetal plasma ACTH concentrations double between 120 and 136 d and 140 and 143 d gestation. In the current study, fetal plasma ACTH concentrations did not increase in the control group but doubled in the FX group on infusion d 7.
One possibility is that FX treatment induced a premature increase in fetal ACTH at an earlier gestational age (mean 134.5 Ϯ 1.0 d). Alternatively, FX may have acted within the fetal HPA axis either to increase the secretion of the hypothalamic secretagogues, CRH or AVP, or to enhance the sensitivity of the corticotrophs within the fetal pituitary to the actions of CRH or AVP.
Previous studies have reported an increase in plasma cortisol levels in fetal lambs in late gestation, beginning about 9 d before delivery (34, 35) . In the current study, this corresponds to infusion d 5 and 4 in control and FX-exposed fetuses, respectively. Thus, the increase in plasma cortisol concentrations between infusion d 4 and 8 in both the control and FX groups is likely to represent the start of the prepartum rise in cortisol. In the present study, we found that the increase in fetal cortisol was greater in the FX-treated group on infusion d 5-8, and that plasma cortisol concentrations appeared to be higher in this group at any given ACTH concentration. This suggests that the fetal adrenal sensitivity to ACTH may have increased in the FX group (36) . It is possible that FX treatment resulted in a stimulation of the secretion of proopiomelanocortin (POMC) products other than ACTH from the fetal pituitary. It has been shown that N-POMC 1-77 has a stimulatory action on fetal adrenal growth and steroidogenic enzyme expression during late gestation (34) . An alternative possibility is that FX acted in the fetal CNS to increase stimulation of the fetal adrenal by the cholinergic preganglionic splanchnic nerve. It has been demonstrated that the splanchnic nerve plays a role in the modulation of the adrenal responsiveness to ACTH stimulation (37) .
Acute hypoxemia and acidemia are potent stimuli for ACTH and cortisol release in the fetus (31, 38 -44) . Although there were small decreases in fetal arterial PO 2 in the FX groups during the infusion period, the fetal arterial PO 2 values did not fall below levels associated with a pituitary-adrenal response to fetal hypoxemia in either acute or chronic studies (39, 40) . It is therefore unlikely that the changes in fetal blood gas status contributed to the fetal pituitary-adrenal response to maternal FX infusion.
It has previously been shown that cortisol plays a role in the regulation of fetal blood pressure. An intrafetal infusion of cortisol for 24 h during the period between 103 and 120 d gestation resulted in an increase in fetal plasma cortisol concentrations to levels similar to those observed close to term and a concomitant increase in blood pressure (45) . Although changes in fetal blood pressure and heart rate were observed in the first 24 h after FX infusion (12) , these changes are not associated with changes in fetal cortisol concentrations and there were no changes in either maternal or fetal blood pressure and heart rate during the 8-d FX infusion period. Although infusion of cortisol between 103 and 120 d gestation resulted in an increase in fetal blood pressure, infusion of cortisol for a 24-h period between 130 and 137 d did not result in any change in fetal arterial blood pressure, and it is likely that further elevations of fetal cortisol above those levels normally present during the prepartum period will not result in further elevations in fetal blood pressure (45) .
Maternal FX plasma concentrations rose on each day of the experiment, but were within the human therapeutic range of 35-415 ng/mL (12, 46) . Changes in fetal plasma ACTH and cortisol concentrations were not observed during the first 5 d of FX treatment despite high plasma FX concentrations. This may be related to serotonin receptor function. One of the effects of the rise in extracellular serotonin elicited by FX and other SSRIs is to down-regulate the 5-HT 1A autoreceptors that inhibit the firing of serotonergic neurons in the raphe nucleus. However, in adults, this appears to require 2-3 wk of FX treatment (47) . In the fetus, the development of the brain serotonin system begins early in gestation, with serotonin immunoreactive perikarya present in the 110 d gestation sheep fetus with well-developed neuritic processes (48) . During development, serotonin receptors may be more susceptible to down-regulation than in the adult. In rats, increased serotonin concentrations during pregnancy induced through a tryptophan-enriched diet or through 5-methoxytryptophan treatment delays serotonin axon outgrowth and/or decreases collateral sprouting, synapse formation, and induces receptor downregulation (49, 50) . Pharmacodynamic modelling was performed to determine whether there was a relationship between maternal or fetal FX concentrations and ACTH or cortisol concentrations but no correlations were found (data not shown).
Our data show that maternal FX administration increases fetal plasma cortisol concentration during late gestation. Previously we have reported that maternal FX infusion reduces the incidence of low-voltage/rapid eye movement (LV/REM) behavioral state in the fetal lamb, and that this effect persists for the entire 8-d infusion period (29) . Thus, FX exposure alters the level of activation of both the HPA axis and fetal behavior (13) and these alterations could underlie some of the postnatal consequences observed in human infants exposed prenatally to SSRIs (7, 9 -11) . What is not yet clear is whether the FXelicited alterations in the fetal HPA axis persist beyond the period of drug exposure and into the postnatal period. Study of postnatal HPA function after in utero SSRI exposure is required to substantiate this possibility. It has been shown in experimental animal studies that exposure to synthetic glucocorticoids during late gestation results in a subsequent increase in blood pressure, in the hepatic production of glucose and in basal cortisol concentrations in adult life (51) . Thus exposure to excess glucocorticoids in utero as a consequence of exposure of the fetus to therapeutic agents such as the synthetic glucocorticoids used in the treatment of threatened preterm labor (52) or the SSRIs may have consequences for fetal and postnatal health.
